Halozyme Therapeutics Retained Earnings (Accumulated Deficit) 2010-2024 | HALO

Halozyme Therapeutics retained earnings (accumulated deficit) for the quarter ending June 30, 2024 were $0.261B, a 85.56% increase year-over-year.

  • Halozyme Therapeutics retained earnings (accumulated deficit) for 2023 were $0.091B, a 36.77% decline from 2022.
  • Halozyme Therapeutics retained earnings (accumulated deficit) for 2022 were $0.143B, a 343.1% decline from 2021.
  • Halozyme Therapeutics retained earnings (accumulated deficit) for 2021 were $-0.059B, a 87.59% decline from 2020.

Halozyme Therapeutics Retained Earnings (Accumulated Deficit) 2010-2024 | HALO

  • Halozyme Therapeutics retained earnings (accumulated deficit) for 2023 were $0.091B, a 36.77% decline from 2022.
  • Halozyme Therapeutics retained earnings (accumulated deficit) for 2022 were $0.143B, a 343.1% decline from 2021.
  • Halozyme Therapeutics retained earnings (accumulated deficit) for 2021 were $-0.059B, a 87.59% decline from 2020.